ArticleJournal of nanobiotechnology2026
Functionalized metal-organic framework-based photosensitive hydrogel eye drops for inhibition of corneal neovascularization and promotion of epithelial repair.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in loading-release-repair strategies of hydrogels for anterior segment disease therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCorneal neovascularization is a common pathological feature of various corneal disorders, often leading to severe visual impairment or blindness. Current therapeutic approaches are limited by low bioavailability and considerable side effects. The development of corneal neovascularization is closely associated with inflammatory responses, which not only promote aberrant vascular growth but also compromise corneal epithelial integrity. During this process, rapid responses from corneal epithelial and immune cells result in the release of cytokines and chemokines, influencing tissue repair. Therefore, effective modulation of inflammation and restoration of epithelial structure are critical for the prevention and treatment of corneal neovascularization.
methodsIn this study, we developed a multifunctional photosensitive adhesive hydrogel eye drop, GelMA-OHA/ZIF8@BMP4. The hydrogel was constructed from an interpenetrating network of methacrylated gelatin and oxidized hyaluronic acid, with bone morphogenetic protein 4 encapsulated within zeolitic imidazolate framework-8 nanoparticles to enable sustained release. The multifunctional therapeutic effects of GelMA-OHA/ZIF8@BMP4 were evaluated in vitro, along with its regulatory effects on the PI3K/Akt and TGF-β signaling pathways. In vivo, a rat corneal neovascularization model was employed to assess the effects of GelMA-OHA/ZIF8@BMP4 on neovascular length and area, corneal edema, epithelial cell proliferation, and corneal ultrastructure, including microvilli, intercellular junctions, superficial epithelial layers, and the basement membrane.
resultsGelMA-OHA/ZIF8@BMP4 demonstrated potent multifunctional therapeutic effects in vitro, effectively modulating PI3K/Akt and TGF-β signaling. In vivo, GelMA-OHA/ZIF8@BMP4 significantly reduced neovascular length and area, alleviated corneal edema, suppressed abnormal epithelial proliferation, and restored corneal ultrastructure, indicating effective inhibition of inflammatory responses and protection of epithelial integrity.
conclusionGelMA-OHA/ZIF8@BMP4 prevents corneal neovascularization formation through suppression of inflammation and promotion of epithelial repair, exhibiting favorable therapeutic efficacy and safety. This study underscores the potential of a controlled-release hydrogel strategy, independent of exogenous cells or growth factors, for the treatment of inflammation-associated corneal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.